RYI-018: A Monoclonal Antibody Cannabinoid Receptor 1 Inverse Agonist For The Treatment of Metabolic Diseases

被引：0
|
作者：
Kretz-Rommel, Anke [1 ]
Ferrini, Roger [1 ]
Mann, Derek [2 ]
Shi, Lei [3 ]
Yang, Teddy [3 ]
Glicklich, Alan [1 ]
Grayson, Paul [1 ]
机构：
[1] Bird Rock Bio Inc, La Jolla, CA USA
[2] Newcaste Univ, Fac Med Sci, Newcastle Upon Tyne, Tyne & Wear, England
[3] RuiYi, Shanghai, Peoples R China
来源：
HEPATOLOGY | 2016年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1153
引用
下载
收藏
页码：581A / 581A
页数：1
相关论文
共 50 条
  • [21] Pharmacokinetics of digoxin in healthy subjects receiving taranabant, a novel cannabinoid-1 receptor inverse agonist
    Andrew E. Denker
    Gaetano Morelli
    Laura K. Vessey
    Susie Li
    Jinyu Yuan
    Stephanie Dunbar
    Nicole M. Lewis
    William Taggart
    John A. Wagner
    Advances in Therapy, 2009, 26 : 230 - 240
  • [22] Pharmacokinetics of digoxin in healthy subjects receiving taranabant, a novel cannabinoid-1 receptor inverse agonist
    Denker, Andrew E.
    Morelli, Gaetano
    Vessey, Laura K.
    Li, Susie
    Yuan, Jinyu
    Dunbar, Stephanie
    Lewis, Nicole M.
    Taggart, William
    Wagner, John A.
    ADVANCES IN THERAPY, 2009, 26 (02) : 230 - 240
  • [23] In vitro and in vivo metabolism of a novel cannabinoid-1 receptor inverse agonist, taranabant, in rats and monkeys
    Reddy, V. B. G.
    Doss, G. A.
    Karanam, B. V.
    Samuel, K.
    Lanza, T. J., Jr.
    Lin, L. S.
    Yu, N. X.
    Zhang, A. S.
    Raab, C. E.
    Stearns, R. A.
    Kumar, S.
    XENOBIOTICA, 2010, 40 (09) : 650 - 662
  • [24] Treatment with anandamide, a cannabinoid 1 receptor agonist, increases the severity of edematous acute pancreatitis
    Dembinski, Artur
    Warzecha, Zygmunt
    Cieszkowski, Jakub
    Pawlik, Wieslaw W.
    Sendur, Ryszard
    Tomaszewska, Romana
    Kusnierz-Cabala, Beata
    Naskalski, Jerzy W.
    Konturek, Peter C.
    GASTROENTEROLOGY, 2006, 130 (04) : A383 - A383
  • [25] Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders
    Scheen, Andre J.
    Paquot, Nicolas
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 23 (01) : 103 - 116
  • [26] A selective inverse agonist for central cannabinoid receptor inhibits MAPK activation stimulated by insulin or IGF1
    Casellas, P
    Bouaboula, M
    Perrachon, S
    Milligan, L
    Canat, X
    Rinaldi-Carmona, M
    Portier, M
    Pecceu, F
    Maffrand, JP
    Le Fur, G
    BRITISH JOURNAL OF PHARMACOLOGY, 1997, 122 : U29 - U29
  • [27] Structure of a Thyrotropin Receptor Monoclonal Antibody Variable Region Provides Insight into Potential Mechanisms for its Inverse Agonist Activity
    Chen, Chun-Rong
    McLachlan, Sandra M.
    Hubbard, Paul A.
    McNally, Randall
    Murali, Ramachandran
    Rapoport, Basil
    THYROID, 2018, 28 (07) : 933 - 940
  • [28] The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice
    Fichna, J.
    Sibaev, A.
    Salaga, M.
    Sobczak, M.
    Storr, M.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2013, 25 (08): : E550 - E559
  • [29] A novel oral cannabinoid receptor-1 inverse agonist induces additive weight loss and improves metabolic biomarkers in DIO mice in combination with semaglutide or tirzepatide
    Morningstar, M.
    Ferreira, S.
    Kolodziej, A.
    Blumen, T.
    Jin, Z.
    Deng, H.
    White, B.
    Brake, R.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S293 - S293
  • [30] Influence of taranabant, a novel cannabinoid 1 receptor (CB-1R) inverse agonist, on the pharmacokinetics and pharmacodynamics of warfarin.
    Schwartz, J.
    Yuan, J.
    Li, S.
    Gipson, A.
    Rosko, K.
    Zakson, M.
    Lasseter, K. C.
    Wagner, J. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S22 - S22
12345